Developments with investigational Janus kinase inhibitors for rheumatoid arthritis (original) (raw)
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical
Yoshiya Tanaka
Modern Rheumatology, 2013
View PDFchevron_right
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside
Yoshiya Tanaka
Journal of Biochemistry, 2015
View PDFchevron_right
Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
Kay Myint, Soe Moe
ISRN Rheumatology, 2013
View PDFchevron_right
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
Peter Taylor
Rheumatology, 2019
View PDFchevron_right
Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
Nandini Kishore
Journal of Pharmacology and Experimental Therapeutics, 2013
View PDFchevron_right
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
Jonathan French
Arthritis & Rheumatism, 2012
View PDFchevron_right
Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Przemyslaw Kotyla
BioMed Research International
View PDFchevron_right
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Alan Kivitz
The Journal of Rheumatology, 2014
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies
Erika García, Karina Santana, Daniel Xavier Xibille Friedmann
Reumatología Clínica, 2017
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies
Erika García, Karina Santana, Daniel Xavier Xibille Friedmann
Reumatología Clínica, 2017
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Jamie Geier
Annals of the rheumatic diseases, 2015
View PDFchevron_right
Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response
Olli Silvennoinen
Frontiers in Immunology, 2021
View PDFchevron_right
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
Francesco Scaglione
Biomolecules, 2020
View PDFchevron_right
Janus Kinase Enzyme (Jak) Inhibitors and Rheumatoid Arthritis: A Review of the Literature
hana morrissey
International Journal of Current Pharmaceutical Research
View PDFchevron_right
[Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis]
Bent Deleuran
PubMed, 2017
View PDFchevron_right
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
Andrzej Pilc
Clinical Rheumatology, 2013
View PDFchevron_right
Kinase Inhibition — A New Approach to the Treatment of Rheumatoid Arthritis
David Fox
New England Journal of Medicine, 2012
View PDFchevron_right
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
Joel Kremer
International Journal of Rheumatic Diseases, 2016
View PDFchevron_right
A Randomized Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Mark Genovese
Arthritis & rheumatology (Hoboken, N.J.), 2016
View PDFchevron_right
A Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-TNF Therapy
Paul Emery
Arthritis & rheumatology (Hoboken, N.J.), 2016
View PDFchevron_right
Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic DMARDs in the treatment of moderate-to-severe rheumatoid arthritis
Mark Genovese
Arthritis & rheumatology (Hoboken, N.J.), 2017
View PDFchevron_right
The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib
Gabriella meszaros
Clinical and experimental rheumatology, 2019
View PDFchevron_right
Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial
vibeke strand
Arthritis Care & Research, 2016
View PDFchevron_right